Anthem (NASDAQ:ANTX) Insider Joshua Eizen Sells 2,826 Shares of Stock

Key Points

• Insider Joshua Eizen sold 2,826 shares for about $11,926, citing tax-withholding obligations tied to vested equity awards; he retained 207,546 shares.
• ANTX shares rose 1.3% on Friday to $4.00. The company reported a quarterly loss of $0.18 per share in its latest earnings results.
• Analysts have a consensus “Hold” rating and an average price target of $9.00; institutional investors own 90.47% of the stock.

Anthem, Inc. (NASDAQ:ANTX - Get Free Report) insider Joshua Eizen sold 2,826 shares of the company's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $4.22, for a total value of $11,925.72. Following the completion of the sale, the insider owned 207,546 shares in the company, valued at $875,844.12. This represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anthem Stock Up 1.3%

Shares of ANTX traded up $0.05 during trading hours on Friday, reaching $4.00. 240,356 shares of the company traded hands, compared to its average volume of 595,404. The stock has a market capitalization of $150.94 million, a PE ratio of -3.74 and a beta of -0.93. The stock has a fifty day simple moving average of $4.78 and a 200 day simple moving average of $4.10. Anthem, Inc. has a fifty-two week low of $1.00 and a fifty-two week high of $7.19.

Anthem (NASDAQ:ANTX - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter.

Analyst Ratings Changes

Several brokerages recently issued reports on ANTX. Weiss Ratings reissued a "sell (d-)" rating on shares of Anthem in a research note on Friday, October 2nd. Guggenheim initiated coverage on shares of Anthem in a research note on Monday, July 20th. They issued a "buy" rating and a $9.00 target price for the company. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Anthem currently has a consensus rating of "Hold" and an average price target of $9.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citizens Financial Group Inc. RI purchased a new position in shares of Anthem in the 2nd quarter worth about $1,443,000. ADAR1 Capital Management LLC acquired a new position in shares of Anthem in the 1st quarter valued at about $47,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Anthem during the 1st quarter worth about $54,000. Velan Capital Investment Management LP purchased a new stake in shares of Anthem during the 2nd quarter worth about $194,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Anthem during the 1st quarter worth about $683,000. Institutional investors and hedge funds own 90.47% of the company's stock.

About Anthem

An2 Therapeutics, Inc is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).

Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.